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Abstract
The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic
resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017.
Over three days of invited plenary lectures, round table discussions and dialogue board
deliberations, participants critically assessed the current state of PET/MRI, both clinically and as
a research tool, and attempted to chart future directions. The meeting addressed the use of PET/
MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain
syndromes, as well as deeper discussions about how best to characterise the tumour
microenvironment, optimise the complementary information available from PET and MRI, and
how advanced data mining and bioinformatics, as well as information from liquid biomarkers
(circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more
complete characterisation of disease phenotype. Some issues that have dominated previous
meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were
finally put to rest as having been adequately addressed for the majority of clinical situations.
Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus
removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned
whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in
many circumstances it would best be employed to give an in-depth study of previously identified
disease in a single organ or region. The meeting concluded that there is still much work to be
done in the integration of data from different fields and in developing a common language for all
stakeholders involved. In addition, the participants advocated joint training and education for
individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our
understanding of normal and disrupted biology, and we are in a position to describe the in vivo
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nature of disease processes, metabolism, evolution of cancer and the monitoring of response to
pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine
and patient care.
Key words: PET/MRI, MR-PET, Hybrid imaging, Molecular imaging, PET/CT, PET, MRI,
Quantification, Infection, Inflammation, Oncology, Neurology, Multi-parametric imaging
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Introduction
The 6th annual positron emission tomography (PET)/
magnetic resonance imaging (MRI) workshop in the
university town of Tübingen, Germany, was held over
March 27–29, 2017. The initial Tübingen workshop in
2012 was the first of its kind to be specifically devoted to
addressing methodological, clinical and research aspects of
hybrid imaging using PET/MRI [1]. Attendees at the current
workshop came from virtually all continents with the
majority originating from Europe and only one in five
having attended past workshops.
In the time since the previous workshop of 2016, the use
of PET/MRI has continued to expand at a similar rate as it
has done since its introduction [1–5]. To say this in a
different way would be that the installation rate of new PET/
MRI systems has not been as remarkable as that previously
witnessed with the initial introduction of PET/X-ray com-
puted tomography (CT). Instead, barriers to installing PET/
MRI remain significant: the capital cost of the equipment,
high recurrent operating costs, lack of appropriately trained
staff to operate and interpret the PET/MRI studies and the
lack of an evidence base demonstrating a proven role for this
form of hybrid imaging in clinical use. The past 12 months
have, however, seen accelerating expansion in Asia in
particular, and hence, the use of the term global warming
for this year’s summary descriptor to capture the mood of
the workshop as PET/MRI is now truly a global tool with
increasing use, especially clinically, thus reflective of a
general Bwarming^ of the imaging community to the value
of the technology. Another factor aiding the continuing
increase in acceptance of PET/MRI is that the design of the
systems, which originally came in a variety of configura-
tions, appears now to have settled on one in which the two
modalities are fully integrated in a single gantry thus
permitting simultaneous acquisitions with both modalities.
At times, debate at previous Tübingen workshops was
dominated by issues that were considered to be technically
deficient or compromised in the early systems, such as how
to use MRI-based image sequences to produce appropriate
correction maps to compensate for photon attenuation in the
PET images [2, 3]. As long as issues such as these remained
unanswered, it was difficult to focus on developing future
concepts for maximally exploiting PET/MRI. It was agreed
at this workshop that this particular issue was finally solved
to a level of accuracy sufficient for the majority of clinical
applications and/or to a level comparable to that seen in
PET/CT, i.e. overall uncertainties seen with PET/MRI are no
worse than those seen in PET/CT and were considered to be
clinically acceptable. One participant during the Physics and
Instrumentation dialogue board even called the topic of
MRI-based attenuation correction a Bcase closed^, if only for
applications of PET/MRI of the adult brain in the intact
skull. Yet, it needs to be acknowledged that as with PET/CT,
a careful inspection of PET/MRI image quality and
quantification remains warranted. Hence, it was noticeable
at this year’s meeting that more discussion was devoted to
future applications of PET/MRI than previously, with a
desire to begin Bgoing deeper^ into the interrogation of the
information contained in the images.
As in the previous meetings’ reports, we will attempt to
provide succinct summaries of highlight lectures, dialogue
boards and major outcomes of the discussion boards.
Likewise, we will highlight progress achieved, or lack
thereof, in specific areas. Finally, we will adhere again to
the general conventions of previous reports to indicate
progress (↑), steady state (↔) and regression (↓) in key
aspects of PET/MRI. The key to the summary tables of
changes in PET/MRI with respect to the status of the
previous year is shown in Table 1.
Finally, as the style of the lectures and discussions was
slightly changed for this year’s workshop in an attempt to
venture into detailed discussions of selected applications of
PET/MRI, we will not follow the previous convention of
detailing new evidence, which has emerged and future
challenges in each area, but rather we will attempt to capture
the recurring themes that emerged during the discussions.
Highlight Lectures
Highlight Lecture 1: PET/MRI Workflow
The 2017 meeting started with an invited presentation on the
considerations and challenges when developing optimised
workflows for PET/MRI. There are a number of key
considerations for operating a PET/MRI system clinically.
First, the economics/logistics are much more challenging
than for PET/CT. Second, PET/MRI scans are far more
demanding on readers. Finally, the scans are more expensive
than PET/CT. The lecture suggested some niche clinical
roles for PET/MRI and compared it to stand-alone imaging
with the other modalities (Table 2).
It was suggested that the workflows that have been
developed for PET/MRI in neurology and cardiology are
straightforward [6]. A simple neurological PET/MRI exam-
ination with 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG)
can be completed in 20 min, whilst a comprehensive multi-
parametric protocol using a F-18-labelled amyloid ligand for
the assessment of dementia might require at least 45 min;
however, all imaging is captured in a single session.
Similarly, in cardiology, a complete examination can be
achieved in around 45 min, as the imaging of a single organ
is ideally suited to PET/MRI. An example of the comple-
Table 1. Key to current status of PET/MRI
↑ Documented evidence of improvement in science and methodology
↗ Suggestion of improvement in methodology, but requires further
investigation
↔ No change, but satisfactory status since previous workshop
↘ Little advancement in science and methodology despite previous
recognition of need for improvement
↓ Less clear evidence than previously suggested
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mentary nature of PET and MRI in cardiology would be to
use [18F]FDG to assess myocardial viability whilst using
MRI to assess perfusion and other parameters (wall motion,
etc) [3], or to use absolute PET perfusion measurements in
conjunction with scar tissue evaluation from late enhance-
ment MRI.
The workflows in oncology, however, are rather
challenging and it may be that for adult patients PET/
MRI imaging could be restricted to studying primary
(target) lesions, a single body region (e.g., thorax,
abdomen, pelvis) or organ (e.g., brain, heart, liver,
pancreas) using BPET/CT guidance^. As a consequence
of lengthy MR protocols resulting in longer available
time to acquire the PET scan, the amount of radioactivity
administered could be reduced (and hence decrease
radiation exposure to the subject), or the adoption of
continuous list-mode dynamic acquisitions and subse-
quent modelling and parametric PET image generation.
As one of the main roles for PET/CT in oncology today
is in staging the extent of disease for metastasis (M) and
nodal spread (N)—and less so for primary tumour (T)
staging—it may be that the role which emerges for PET/
MRI reverts more to characterising the primary tumour,
perhaps using non-FDG radiopharmaceuticals. For exam-
ple, one could conceive of a protocol where a dynamic
PET/MRI scan is acquired from injection of the
radiopharmaceutical up to 30–60 min over the region
containing the primary tumour, to capture all of the MRI
sequences of interest and the PET kinetics of uptake in
the primary lesion, and then the patient is taken for a
conventional whole-body staging PET/CT scan com-
mencing 60–90 min after injection to complete the
metastasis and nodal evaluation. This concept has been
proposed as early as 2009 by Hicks and Lau [7].
Reiterating discussions from previous Tübingen work-
shops, the use of DWI-MRI in patients with [18F]FDG
avid primaries and lymph nodes was considered obsolete
[4]; however, MRI, including DWI, expresses a high
sensitivity and specificity for small liver lesions even
though the [18F]FDG-PET may be negative.
Highlight Lecture 2: Image-Guided Radiotherapy
The second highlight lecture was dedicated to the value
of image-guided radiation therapy. Over the past years,
wide-bore PET/MR systems that can serve the demands
of the dedicated radiotherapy equipment have been
designed and are being used. In this lecture, the value
of [18F]FDG-PET for individualised target volume
delineation, e.g. in lung cancer patients, was briefly
reviewed. Moreover, the use of non-[18F]FDG radio-
tracers in radiation treatment planning (RTP) and
monitoring of response was emphasised. Clinically, the
ability to monitor hypoxia and re-oxygenation during
combined radio-chemotherapy offers the radiation oncol-
ogist greater insight into potential response during
treatment, which should ultimately lead to better
outcomes.
Prospective clinical studies personalising treatment on the
basis of hypoxia-PET readout are being designed or have
started patient accrual. 3′-Deoxy-3′-[18F]fluorothymidine
([18F]FLT) depicting another relevant tumour characteristic
in radiotherapy, i.e. tumour cell proliferation, was shown to
be of predictive value in head and neck squamous cell
carcinoma patients; however, the limited availability of the
tracer has hindered its wider adoption in larger clinical trials
and ultimately clinical routine. In theory, [18F]FDG-PET, the
hypoxia PET-tracers [18F]fluoromisonidazole ([18F]FMISO)
or 3-[18F]fluoro-2-(4-(2-nitro-1H-imidazol-1-yl)methyl)
([18F]HX4), and [18F]FLT-PET may be of additive value in
defining the biological target volume. Furthermore, the
international phase II clinical BPET BOOST^ study in
advanced stage non-small cell lung cancer (ClinicalTrials.gov
identifier: NCT01024829) was mentioned, in which an
enhanced Bboost dose^ is delivered to either the [18F]FDG-
PET avid tumour sub-volumes or to the entire gross tumour
volume whilst maintaining the dose to the surrounding organs
at risk (NCT01024829). Moreover, PET/MR imaging is
increasingly being utilised as an objective measure for normal
tissue toxicity, e.g. radiation-pneumonitis in lung cancer
patients [8] or neurocognitive decline in primary brain tumour
patients, or as an indirect indicator of primary tumour response,
e.g. in HNSCC [9]. A final word of caution addressed the
necessity of geometrically accurate MR images in the era of
image-guided high-precision radiotherapy.
In conclusion, PET/MRI appears to have a number of
potential uses in radiotherapy, including the adoption of
integrated functional imaging to monitor response and
adapt during treatments when significant changes are
observed (Fig. 1). However, cross-specialty studies are
needed that specifically employ radiotracers other than
standard [18F]FDG for both the primary tumour as well
as normal tissue.
Highlight Lecture 3: Imaging the Tissue
Microenvironment
The final highlight lecture presented a tour de force
review of fundamental discoveries related to cancer at
the cellular level which has been suggested as a future
topic of interest for advanced PET/MRI: the assessment
of tumour microenvironment. It was proposed that PET/
MRI might be able to examine similar features seen in
the tumour microenvironment scaled up to the whole
Table 2. Suggested current clinical roles for stand-alone CT, PET and MRI
(courtesy of A Beer, Würzburg)
CT Robust, rapid whole-body assessment
PET BProblem solving^ whole-body tool
MRI BProblem solving^ specific regional imaging tool
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organ or organism level. Some of the parameters
discussed could be implemented already today, since
they are based on existing imaging biomarkers, such as
hypoxia PET agents (e.g. [18F]FMISO) or the imaging of
collagen fibres, that can act as a Bhighway^ along which
cancer cells migrate, using diffusion MRI.
Some studies of cancer cell migration have suggested
focal adhesion kinase (FAK) as a potential therapeutic target
in solid carcinomas. FAK is an intracellular tyrosine kinase
recruited to sites of integrin clustering or focal adhesions and
is a multi-functional regulator of cell signalling within the
tumour microenvironment. FAK is a major mediator of
signal transduction by cell surface receptors including
integrins, cytokine receptors and growth factors and could
even potentially be used to inhibit cells migrating by
adhesion. Based on preclinical evidence presented during
this lecture, a FAK imaging biomarker would be useful to
study this effect in vivo in combination with MRI sequences
of apparent diffusion coefficient (ADC) (collagen distribu-
tion), pH and hypoxia, so as to better our understanding of
the tumour microenvironment.
The tissue macroenvironment and its relationship to
cachexia in cancer patients was also reviewed. Magnetic
resonance spectroscopy (MRS) of lipids and cholesterol in
serum has been shown to be prognostic for cachexia and
builds on the idea of a tumour metabolic Bsecretome^ in
cachexia which could be used for prognostication and/or
monitoring response to treatment using a holistic imaging
approach with PET/MRI.
In light of recent advances in theranostic imaging, a
role for PET/MRI was suggested looking at targeted
prodrug detection and its action in tumours such as the
conversion of 5-fluorocytosine (5-FC) to the active anti-
cancer drug 5-fluorouracil (5-FU) in prostate cancer
treatment, and the prospect of studying the effects of
photo-immunotherapy [10]. These approaches go far
beyond the capabilities of PET/CT and demonstrate
potential unique future applications for PET/MRI.
Dialogue Boards
Dialog Board 1: Physics and Instrumentation
One of the main topics which has dominated discussions in
past workshops has been the accuracy of attenuation
correction (AC) using MR-based techniques. A number of
strategies have been investigated, resulting in over 250
publications over the past several years. Attenuation due to
the MR hardware alone can account for up to 20 % signal
loss in the reconstructed PET image [11–13]. Nevertheless,
there was general agreement between the participants in this
Dialogue Board, and many clinical users, that this issue can
be put to rest since MR-AC has been solved to the degree
required for clinical use based on accepted image metrics.
Sequences, such as ultra-short echo time (UTE) and zero
echo time (ZTE), now provide sufficient information to
identify bone or ancillary positioning aids and coils to aid in
building an accurate attenuation map of the head for PET/
MR neuroapplications [14]. Truncation of the body at the
periphery due to the limited size of the MRI field-of-view
can been mitigated with the B0 homogenization using
gradient enhancement (BHUGE^) correction [15];
implementations of this type or alternative solutions vary
between the manufacturers.
Of note, the variety of available algorithms for MR-
based attenuation correction challenges the clinical
readers. Unlike in PET/CT, where a single fast Bpush-
button^ whole-body CT scan provides all the necessary
information required for AC, similar corrections in PET/
MRI resemble a BLEGO construction kit^: multiple
Bbuilding blocks^ are needed to form a whole-body data
set for attenuation correction in PET/MR: Dixon se-
quences for AC of the soft tissues, UTE and ZTE
sequences to provide the skull bones, bone models to
add major bones, HUGE or MLAA data to correct for
truncation artefacts, and CT-based templates to correct
for RF coils and the patient table. It is clear that this
Fig. 1. Patient with oropharyngeal carcinoma pre- and post-RT. a [18F]FDG-PET/CT prior to RT. Oral mucosa delineated in
pink, clinical target volume (CTV) in red. b [18F]FDG-PET/CT during week 4 of RT. For the analysis, the CTV was subtracted
from mucosa. ( Courtesy of S. Zschaeck, MD, Charité Berlin)
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rather complex approach of PET/MR attenuation correc-
tion is prone to errors and requires thorough integration
to provide the Bpush-button^ ease of use, accuracy and
robustness of the CT component for AC in PET/CT.
In light of the above discussions, it was agreed that
although numerous methods for AC in PET/MRI have been
developed and evaluated in various studies, not all of these
different techniques have found their way as product
versions into the existing PET/MRI systems. Thus, the
PET/MRI community faces the situation that at single sites
some methods are available, whilst others use different
methods, different vendors and different AC applications.
This leads to a certain inhomogeneity when using different
AC methods, as not only one single version of AC exists as
is the case for PET/CT. This also emphasises the further
need towards standardisation efforts in PET/MRI attenuation
correction.
The meeting was reminded, however, that the reproduc-
ibility of SUVmax measurements with [
18F]FDG PET/CT can
be of the order of up to ± 50 % as shown in a study where
subjects were scanned on two consecutive days [16]. These
differences are due to many factors including biological and
instrumentation components, and small differences in atten-
uation correction factors between methods should be viewed
in this context.
The ability of PET data and MRI data to be used in the
image reconstruction of the other modality (i.e. MR-
informed PET reconstruction, PET-informed MRI recon-
struction) has previously been suggested and explored [17].
The dialogue board concluded that using the MRI data can
definitely have an impact and improve the spatial resolution
and image quantification of PET images (Fig. 2), but the
PET data have not yet provided any discernible improve-
ment in the MRI reconstructions due to their poorer spatial
resolution. Motion detected in the MRI scans can be used to
correct for motion in both the MRI and PET data during the
reconstruction process [14]. First implementations of these
techniques are becoming available on commercial PET/MRI
systems. Finally, one further comment on attenuation
correction was added in that the accuracy of the attenuation
correction could be further improved using time-of-flight
information from the PET data, if available, in the MLAA
algorithm [18–20]. This is now being actively pursued with
the emergence of time-of-flight (ToF) PET/MRI systems.
Yet, even without MLAA, improved image quality can be
achieved by the use of improved ToF in regular ToF OSEM
and it was shown that ToF already mitigates MR-based
attenuation correction artefacts [21].
Table 3 summarises the progress made in the areas of
PET/MRI physics and instrumentation. Of note, no such
Fig. 2. Joint PET and MR image reconstruction. Simulated PET and undersampled (5 of 8 coils) T1-w MR data. First
independent reconstructions were performed, using least squares reconstruction with joint total variation (TV) prior to MR and
ML reconstruction with a TV prior to PET. Then, a simultaneous MR and PET reconstruction with the joint TV prior was
performed. The resolution of the PET image improves a little, whilst the changes to the MR image appear very minor at best
(courtesy of J Nuyts, Leuven/BE).
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dedicated session was scheduled for the 4th (2015) or 5th
(2016) workshops, when these topics were dealt with as part
of the clinical topics. Overall, progress was made in all of
the key areas. As discussed above, the accuracy and
robustness of MR-AC methods are well understood, and
research endeavors are now turning to the validation of new
concepts for multi-parametric imaging, such as the adoption
of an image-derived arterial blood input function [22].
Dialogue Board 2: Oncology—Status Quo
The session started with a review of the current evidence for
the role of PET/MRI in oncology (Table 4). From this, the
areas where evidence exists that PET/MRI has been
demonstrated to provide better information and characteri-
sation of disease are in prostate cancer [23] and, as
suggested previously at these workshops, in paediatric
oncology [42]. Areas where new evidence is emerging
include gastrointestinal cancers [43, 44], breast cancer [40,
41], gynaecological malignancies [37] and hepato-
pancreatobiliary cancers [45]. The value of PET/MRI in
these applications was seen again to be in a comprehensive
regional evaluation and not in Bwhole-body^ applications; as
stated by one of the panellists: BThe added value of PET/
MRI starts locally^.
The dialogue board continued with a discussion of PET/
MRI tissue characterisation and molecular diagnostics. It
was felt that modern oncology practice is making its greatest
advances today in DNA sequencing/phenotyping to guide
the use of targeted therapies. This information can be
transformed into knowledge about Btumour resistance^,
which, it was suggested, is more likely attributable to clonal
evolution producing heterogeneity [46]. This message was
reinforced later in the symposium in the dialogue board on
emerging areas and discovery (see below). PET/MRI was
reported to be extremely valuable in avoiding sampling
errors during biopsy caused by tumour heterogeneity [47].
Rather than trying to minimise the amount of scanning
that would be performed, it was suggested that primary
tumour characterisation for an individual might require
multiple probes to characterise the individual disease; one
example given was in the evaluation of primary lesions in
hepatocellular carcinoma (HCC) using both [18F]FDG and
[18F]fluorocholine (FCh). Whereas previously the value of
[18F]FDG in HCC has been questioned due to the different
glycolytic pathways that the tumour can access [48] leading
to a negative [18F]FDG signal, it was argued that the best
understanding of the tumour biology and heterogeneity
would be attained by performing both scans to better
understand the regional phenotype of the heterogeneous
cancer cells. This is akin to the approach taken in PET
imaging of neuroendocrine tumours using a somatostatin
receptor radiopharmaceutical such as [68Ga]DOTATATE
combined with [18F]FDG [49, 50].
The characterisation of HCC can be regarded as a
molecular extension to the concept of radiomics, which has
been applied primarily to anatomical image analysis in
combination with non-imaging biomarkers. By integrating
molecular imaging information with radiomics, we move to
a Bradiomics+^ concept that is one step closer to Bin vivo
pathology^, which has the potential to become the standard
in the near future for oncology patient management.
The theme of multi-parametric imaging and tumour
heterogeneity continued in the presentations and discussions.
In pancreatic adenocarcinoma, three distinct phenotypes
with different genetic subtypes have been identified that
exhibit different metabolic subtypes following either glyco-
lytic or lipogenic pathways, or a combination of both [51]. A
novel technique (Fig. 3) for spatially aligning surgical
resection specimens with the images from PET/MRI was
described using a histopathological processing algorithm
based on a 3-D print mould generated from pre-operative
in vivo imaging, enabling accurate co-registration between
the excised tissue and the in situ imaging data. A multi-
parametric analysis comparing [18F]FDG SUV versus ADC
from MRI was used to classify heterogeneity and is a
potential target area of application for ML-based clustering
of physical tissue compartments.
Table 5 summarises the status quo of PET/MRI in
oncology. Generally, the use of PET/MRI for oncology
indications continues to grow and methodological progress
has been made continuously. Unfortunately, the community
still lacks a set of standardised acquisition protocols
(pending the engagement of the medical specialists’ organi-
sations), and further efforts are needed to resolve residual
bias from MR-AC, the presence of truncation artefacts and,
more importantly, motion effects.
Dialogue Board 3: Oncology—Where to Go?
This dialogue board addressed the theme of how PET/MRI
can best complement the latest developments in oncology
therapeutics. As immunotherapy is one of the hottest topics
at present in oncology, discussion centred on whether it
could be improved by the use of functional imaging
techniques. Additionally, the discussants considered how
Table 3. Progress of physics and instrumentation developments since the
first workshop
Feature 2012 2013 2014 2015 2016 2017
Critical evaluation of MR-AC
methods
↗ ↑ ↑ – – ↑
Validation of MR-based motion
correction
↔ ↔ ↗ – – ↗
Agreement on acceptable lower
limits of quantitative accuracy
of PET following MR-AC
↘ ↘ ↔ – – ↗
Clinical introduction of advanced,
MR-based quantitative parame-
ters (e.g. image-derived input
functions)
↓ ↘ ↘ – – ↗
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the latest developments in relatively non-invasive tumour
phenotyping using liquid biopsy could be combined with the
results of imaging of lesion heterogeneity using PET/MRI.
Liquid biopsy of circulating tumour cells and DNA or
miRNA is playing an increasing role in screening and early
detection (especially in recurrence), the detection of micro-
metastases and in the monitoring of therapies where they can
be used as an early indication of response from simple blood
sampling [52, 53]. However, it was recognised that blood-
based tests present a Bglobal^ picture as changes in
phenotype are often observed serially, thus requiring
regional identification, indicating an example of where
liquid biopsy and imaging would perform a complementary
role.
As this dialogue board was addressing the question of
BWhere to Go?^, the role of mouse models and patient-
derived xenografts (PDXs) were discussed. Preclinical
imaging with PET/MRI will likely have a role in these
models along with bioluminescence techniques. Finally, the
understanding of the role of tumour-infiltrating T cells was
considered and whether labelling T cells with Zr-89 or other
nuclides would allow in vivo monitoring to predict response
to immunotherapy (Fig. 4). However, careful selection and
matching of targets, probes and nuclides is required.
Especially, functional impairment by direct targeting of T
cells needs to be excluded.
Panel Discussion: Dialogue Boards 2 and
3—Oncology
The discussion was kicked off with an upfront statement
by one of the panellists who stated Bthe imaging field
was disconnected from oncology for years^, thereby
attesting to another statement below regarding a fre-
quently observed approach towards interpreting results
from imaging examinations in isolation. The panel was
then asked to respond to the question of where they
thought oncological therapy response assessment will be
in 10 years’ time. The initial response was that there is
increasing pressure to predict what response might be
likely to occur in an individual patient, partly due to the
high cost of the therapies. The power of predicting
patient-specific therapy response was felt to be of ever-
Fig. 3. Co-registration of imaging and histopathology data. aWork flow schematic. b Pre-operative T2w image with annotated
resection margins. c 3D print mold. f Fixated axially processed specimen with g annotated tissue blocks. h Stitching of tissue
slices. i Screenshot of in-house written software for co-registration and regional analysis of imaging and histopathology data
(courtesy of Rickmer Braren, Katja Steiger, Franz Irlinger and Maximilian Baust).
Table 5. Progress indicators for PET/MRI in oncology
Feature 2012 2013 2014 2015 2016 2017
Definition of key clinical applications ↔ ↔ ↗ ↗ ↗ ↗
Diagnostic quality of PET in PET/MRI equivalent to PET quality in PET/CT ↔ ↔ ↗ ↗ ↗ ↑
Resolving quantitative bias from MR-AC ↘ ↔ ↔ ↔ ↗ ↗
Clinical data available on diagnostic accuracy of PET(/MRI) in oncology ↔ ↔ ↗ ↔ ↗ ↗
PET/MRI protocol standardisation ↓ ↔ ↘ ↔ ↔ ↔
Clinical evidence on the usefulness of PET/MRI in paediatric oncology ↔ ↗ ↗ ↗ ↔ ↔
Reduced radiation exposure as a key driver for paediatric PET/MRI ↗ ↑ ↑ ↔ ↘ ↘
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increasing importance given the evolution of resistance
of solid tumours to successive lines of therapies. It was
mentioned that 95 % of the oncology drugs fail during
phase 1 trials, which can be regarded as an argument
towards Braising the bar on pre-clinical testing^, i.e.
questioning whether animal models are suitable surro-
gates for predicting efficacy in humans. It was felt that
imaging, and molecular imaging in particular, will be an
increasingly important tool due to the heterogeneity and
evolution seen in disease progression and that ultimately
imaging could be more important than traditional biopsy
in this regard due to its ability to identify evolving
clones. A more careful and systematic validation of
multiple imaging parameters, as provided by PET/MRI,
in the clinical context was considered an important step
busting acceptance of imaging parameters as bio- and
surrogate markers.
The panel was also asked to speculate as to the
appropriate timing of imaging to assess response. After
some discussion, with suggestions from Bas soon as
24 hours^ after commencing treatment to Bnot before 6–
8 weeks^, it was agreed that if the therapy is inducing
senescence [54] then imaging could be used as soon as
2 weeks after commencing therapy. One of the panellists
suggested that we still do not have all of the appropriate
tracers to study cellular biology to match the advances in
oncology today. He suggested that some of the probes
needed to demonstrate tumour stresses during therapy and
the stress support pathways should be able to demonstrate
apoptosis, senescence and hypoxia. The forum’s general
response was that Bwe have the tracers and we have all the
technology and tools, but what we do not understand is what
the signal is telling us at present^. This returned to the theme
of better developing multi-parametric analyses and the role
that predictive analytics may play in this domain; one
attendee summarised it by saying Bwe should stop talking
about the Bimages^, but rather promote the image content as
mineable data, that is, as an imaging assay^.
The discussion moved on to looking at pseudo-
progression in the light of immunotherapies, which is a real
clinical challenge. Thus, imaging strategies need to be
developed to directly track T cells within the tumour
indicating response to treatment and therefore representing
a valuable surrogate marker (Fig. 5). In addition, the ability
to follow-up on treatment response and tumour progression
with the help of liquid biopsies with or without imaging was
discussed. It was concluded that, today, liquid biopsies alone
would not be sufficient to do the job, and that imaging could
add valuable information especially in therapy response
monitoring providing information about the change in
phenotype of known and the location of evolving
(metastatic) disease which may have implications for
subsequently adjusted therapies.
The panel discussion ended with some speculation about
the role that functional imaging could take to assist in
triaging patients appropriately to targeted therapies. It was
felt that some education of regulators and the industry was
still needed to develop a paradigm that would test individual
patients prior to commencing therapy in an attempt to
contain costs and produce better outcomes.
Dialogue Board 4: Neurology—Status Quo
The dialogue board in neurology started by reasserting that
the issue of AC for PET/MRI in neurology was solved to
within the uncertainties associated with the overall proce-
dure for the given modality. The only possible exceptions at
this stage are in the cases of scanning children’s brains using
atlas-based techniques for MR-derived AC or where there
has been prior craniotomy and, therefore, disruption of the
skull contour. This has now resulted in progress in analysing
Fig. 4. Selection of target structures on effector T cells as well as probes and nuclides to develop safe and efficient imaging
strategies to track T cells during immunotherapy (courtesy of Sabine Mall and Angela Krackhardt).
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the data from brain PET/MRI, as previously researchers
were preoccupied with solving the attenuation correction
problem.
Presentations from the panellists documented the current
clinical uses of PET/MRI in neurology as being in studies of
dementia using [18F]FDG, neurodegenerative disorders,
neuro-oncology, epilepsy, a small number of cases of
cerebrovascular disease and various other diverse conditions
including encephalitis and sarcoidosis [56]. The PET/MRI
studies were being used in a variety of ways including
diagnosis, characterising pathology, demonstrating the ex-
tent of neuronal injury and monitoring progression, and
different radioligands can be used depending on the focus of
the examination. The use of imaging biomarkers in
Alzheimer’s disease (AD) with PET/MRI can be performed
in a 20–30-min session including an early image after
injection of the a fluorinated amyloid PET tracer to give a
p e r f u s i o n / BFDG- l i k e^ imag e ( r e g i on a l b l o od
flow/metabolism) that can be compared with the subsequent
image of the binding to cerebral amyloid. Mention was made
of further imaging biomarkers such as the α4β2 nicotinic
acetylcholine receptor which can be imaged using [18F]-
flubatine [57]. Another promising approach to multi-
modality brain imaging, particularly in dementia, utilises
rest state-fMRI in combination with structural MRI and
[18F]FDG PET to determine the functional connectivity
between affected brain areas [58]. Finally, the use of PET/
MRI in neurological imaging trials requires the judicious
choice of an AC method (based on MR sequences or other
modalities) that should stay standard for the duration of the
study. Lastly, it was noted that fully integrated PET/MRI has
proven to be beneficial for fully quantitative brain imaging,
including non-/invasive pharmacokinetic modelling.
Discussion of research in rodents using PET/MRI focused
on investigating the connectivity between metabolism (using
[18F]FDG), perfusion (using [15O]H2O) and fMRI using the
blood oxygen level dependent (BOLD) technique. A number
of interesting results demonstrating both expected correla-
tion in metabolism and perfusion in some brain areas as well
as unexpected disconnections between the same parameters
in other areas were seen [59]. PET/MRI, operating over the
medium to long temporal scale compared to ultra-fast
techniques methods such as electroencephalography (EEG)
and magnetoencephalography (MEG), was seen as the only
way to inves t igate such connect ions ( termed
Bcometomics^—connectivity via metabolomics).
The great strength of PET/MRI in brain imaging, whether
research or clinical, was thought to be the Bone-stop shop^
option, where all of the imaging required to characterise
patient disease could be performed in a single session. This
is also reflected in the continuous progress made in the
applications of PET/MRI for neurology (Table 6). Of
interest, one of the panellists made a point on the
Bsimultaneity of PET and MRI, that had no other advantage
than increase patient comfort and convenience^, which may
have come as a surprise to some PET/MRI users.
Dialogue Board 5: Neurology—Where to Go?
This dialogue board posed the question of whether the
predominant use of brain PET/MRI in the future would be
for routine clinical applications or in research. Ample
evidence was provided that there is an increasing role
clinically for brain PET/MRI [6]. The case was made for the
substitution of imaging biomarkers to objectively diagnose
dementia in place of the current syndromic tools which
clinicians are left to rely upon. With potentially expensive
therapies on the horizon in AD, it was felt that regulators
and medical service providers should be encouraged to use
imaging as an objective biomarker to select the appropriate
Fig. 5. Tracking of intravenously injected T-cell receptor
(TCR)-transduced central memory T cells within antigen-
expressing tumours by Zr-89-labelled aTCRmu-F(ab′)2 using
PET/CT. a TCR-transgenic T cells were injected intrave-
nously after tumour engraftment followed by i.v. injection of
[89Zr]-labelled aTCRmu-F(ab′)2 48 h after adoptive T-cell
transfer. b Heterogeneity of T-cell infiltration, as seen in the
zoom in, has been validated by semi-quantitative analysis
using immunohistochemistry [55] (courtesy of Sabine Mall
and Angela Krackhardt).
Table 6. Progress indicators for PET/MRI in neurology
Feature 2012 2013 2014 2015 2016 2017
Improved understanding of brain
physiology and function
through the use of combined
PET/MRI
↔ ↗ ↗ ↗ ↗ ↗
Methodological progress for
improved quantification of
PET/MRI neurological exami-
nations (AC, IDIF, SUV)
↔ ↔ ↗ ↗ ↗ ↗
MR-based motion correction for
routine clinical use
↓ ↘ ↔ ↔ ↔ ↗
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patients for these therapies as well as to monitor response.
On the research side, elegant work using multi-modality
neuroimaging with pharmacological challenges was shown
which demonstrated that pharmacological PET could be
used to study drug penetration and kinetics, to identify
pharmacodynamic effects, and could be used in drug
occupancy studies which could be combined with simulta-
neous blood flow measurements using arterial spin labelling
[60] as well as functional and structural MR imaging [61,
62].
Addressing the issue of where to go with future brain
PET/MRI studies, the integration of imaging with human
genetics testing was explored. Using next-generation se-
quencing technologies, it is now possible to sequence
hundreds and even thousands of genes in parallel. This
dramatically increases the chance to find the cause of the
disease in many heterogeneous neurologic diseases. From a
diagnostic point of view, panels of genes that are known to
cause a particular disease including all differential diagnoses
can be investigated simultaneously with very high coverage
and, if negative, whole exome or whole genome sequencing
is followed. Next-generation sequencing allows also the
detection of mosaicism in blood and other tissue samples.
Panel Discussion: Dialogue Boards 4 and
5—Neurology
The panel discussion on the neuroscience subjects reflected
the relative maturity and acceptance of PET/MRI in studying
the brain. The panellists agreed that PET/MRI is a
convenient means to an efficient work-up of patients
suspected of Alzheimer’s disease; however, the added
diagnostic benefit of fully integrated PET/MRI in this
patient group was considered to be small.
PET/MRI can help increase patient comfort as well as
provide doctors with the option to perform a wide range of
structural and molecular imaging assessments for disease
characterisation and/or monitoring within a single investiga-
tion. This is of utmost importance for trials comprising a
variety of MRI/fMRI imaging sequences along with exten-
sive and complex pharmacokinetic PET investigations. The
panellists agreed that PET/MRI is capable of providing
molecular imaging-based evidence to support early diagno-
sis/staging/disease and therapy monitoring of dementia and
other brain disorders in clinical routine. Furthermore, it is a
powerful tool in complex research settings of neuroscience
comprising molecular imaging and pharmacokinetic/
pharmacodynamic analysis.
In clinical research, a large number of physiologically
relevant measurements can now be made simultaneously
using PET and MRI including metabolism, neurotransmis-
sion, receptor expression, cerebral blood flow/perfusion,
tissue environment and pathological conditions (e.g. amyloid
deposition). This opens for investigation of fundamental
physiological and neurochemical aspects of, e.g. changes in
neurotransmission in relation to blood flow under physio-
logical or pharmacological stimulation. Such knowledge can
be instrumental to assess drug effects in the individual
patients, and allows for a precision medicine approach. The
next challenge seen by the panellists was how to integrate
these measurements with genetic fingerprinting to delve
more deeply into describing a more comprehensive pheno-
typical classification of disease.
An additional emerging topic might also be the assess-
ment of active plaques in demyelinating diseases like
multiple sclerosis. In addition, the combination of PET/
MRI with fast temporal scale techniques like EEG might
give further insight in pathophysiological processes in the
brain, e.g. in epilepsy.
Dialogue Board 6: Infection and Inflammation
The topics of infection and inflammation imaging were
introduced at last year’s workshop for the first time [5]. At
the time, an enormous number of targets were presented for
potentially imaging infection and inflammation, but there
were relatively few imaging biomarkers specifically devel-
oped to exploit the vast majority of these, and hence
discussion last year centred on adapting well-established
nuclear medicine techniques which have been around for
many years using radiolabelled antibiotics, immune cells and
antibodies, membrane ligands, antimicrobial peptides, iron
metabolism ([67Ga]-citrate) and metabolic tracers. However,
many existing agents fall short of distinguishing infection
from sterile inflammation (e.g. FDG). In contrast, at the
meeting this year, a number of new compounds were
presented for bacteria-specific PET imaging. Non-invasive
anatomical analysis with MRI plus pathogen-specific PET
imaging could significantly improve patient outcomes by
rapidly identifying a source of infection and monitoring the
response to treatment [63].
Imaging of infection has been developed by the Center
for Infection & Inflammation Imaging Research (Ci3R) at
Johns Hopkins University over the past few years. Using a
systematic screening approach, they evaluated a large
number of potential agents for selective bacterial accumula-
tion and found ten compounds that could be used as
bacteria-specific imaging biomarkers, showing interesting
results with para-aminobenzoic acid (PABA), deoxy-
mannitol and deoxy-sorbitol [64]. Among other biomarkers,
they presented results using [18F]fluoro-deoxysorbitol
([18F]FDS), which can be synthesised from radiolabelled
FDG [65]. [18F]FDS is selectively accumulated by gram-
negative Enterobacteriaceae such as Escherichia coli,
Yersinia, Klebsiella, Enterobacter and Salmonella, including
multi-drug-resistant organisms. Using a murine myositis
model, [18F]FDS was able to differentiate infection sites
from sterile infection in immunocompetent and neutropenic
mice, thus suggesting that the uptake is actually by the
bacteria rather than by migrating neutrophils. Potential
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advantages of imaging active infection include a much
earlier path to diagnosis and instituting appropriate antibiotic
therapy rather than waiting for blood cultures (Table 7).
The session then turned to a new area for the
workshop: the imaging of chronic pain and how its
investigation could benefit from the use of [18F]FDG
and PET/MRI. In many Western societies, morbidity and
productivity loss due to chronic pain constitutes one of
the largest burdens on society. Chronic pain was said to
affect more people than those suffering from cancer, heart
disease and diabetes combined. The source of chronic
pain is often difficult to identify and diagnose with
conventional morphological imaging. Bone scanning
using [99mTc]phosphonate has long been known to have
a role in identifying the site of the cause of pain reflected
in increased osteoblastic reactivity—the concept of
Bwhere it’s hot it hurts^ attributed to Schuster. Similarly,
increased PET radiotracer uptake preliminarily appears to
map to areas of increased pain-relevant or pain-generating
pathology, potentially affording clinicians the ability to
make improved image-informed, objective management
decision to minimise pain in chronic pain sufferers. The
MRI component of PET/MRI is considered essential
because of the high spatial resolution and high tissue
contrast which, when combined with the [18F]FDG signal,
can identify the exact location of the inflammatory
response. As soft tissue is involved in many of these
syndromes, PET/CT was thought to be of less value due
to the poorer tissue contrast that is usually seen with CT
compared to MRI. Additionally, because PET and MRI
data sets are acquired simultaneously, the fidelity of the
co-registration of both data sets is likely more accurate
than what can be achieved with PET/CT. Spatial mis-
registration between PET and CT data is a well-known
phenomenon since both data sets are acquired separately
in time and, thus, small patient movements between the
two scan acquisitions can result in PET measurement
errors between small adjacent structures such as a nerve
root and a neighbouring facet joint. The ability to
accurately delineate abnormal radiotracer uptake in a
nerve root versus the facet joint, for example, could be
the difference in a successful outcome since management
decisions are made according to the location of PET
abnormality.
[18F]FDG has been used off-label in a clinical trial to
study patients with complex regional pain syndrome, chronic
sciatica and other pain syndromes. As in the discussion of
infection and inflammation imaging, new imaging bio-
markers of specific targets were being developed and
characterised in human subjects, for example, to identify
sigma-1 receptor (σ1R) ligands such as [18F]FTC-146 in the
setting of chronic pain [66, 67]. Sigma-1 receptors, a unique
class of intercellular chaperone proteins, have a modulatory
role in ion channels and other neurotransmitter systems.
Accordingly, σ1Rs have been found to be important in pain,
inflammation, neuronal protection, neurodegeneration, can-
cer, addiction and psychiatric diseases. Early results have
showed important differences between asymptomatic volun-
teers and those suffering from chronic pain.
Dialogue Board 7: Emerging Areas
The final dialogue board of the workshop addressed the
issue of advances in multi-parametric imaging. The first
contribution looked at how it is now possible to investigate
multiple aspects of tumour metabolism by combining
hyperpolarised C-13-labelled cell substrates with PET
biomarkers, such as [18F]FDG [68, 69]. Dynamic nuclear
polarisation can increase the signal-to-noise ratio in solution
state 13C NMR spectroscopy and imaging experiments by
910,000× [70]. Fundamental questions such as why cancers
have high rates of aerobic glycolysis (Warburg effect) could
potentially be addressed using 1-[13C]pyruvate and
[18F]FDG in animal tumour models. The combination of
magnetic resonance spectroscopic imaging of hyperpolarised
1-[13C]pyruvate, when combined with [18F]FDG to image
glycolysis, and further measures such as hypoxia bio-
markers, could provide insight into cancer metabolism and
tumour heterogeneity and how various pathways (e.g.
HIF1α, MYC, mTOR, PTEN) are involved (Table 8).
The second contribution was on the development of
adaptive therapies and insights into how cancers Bevolve^.
Evolution is driven by the genomic plasticity that is inherent
to cancers, in combination with microenvironmental selec-
tion. As tumours contain multiple microenvironmental
habitats, these will result in distinct lineages of tumour cells
generating intratumoural heterogeneity. Addition of therapy
changes the adaptive landscape and selects for cells that are
resistant. Notably, these resistant clades of cells are often
cross resistant to other therapies, leading to unmanageable
disease [71]. This has been mathematically modelled to
show that emergence of resistance can be forestalled with
adaptive dosing based on tumour response [72]. This is
highly relevant to PET/MRI studies as the monitoring of
response becomes a critical factor in adaptive dosing and in
predicting pathways that the emerging resistant cell lines
may exploit. The large number of probes that can be used
Table 7. Progress indicators for PET/MRI in infection and inflammation
2012 2013 2014 2015 2016 2017
Improved tissue characterisation
by combined PET/MRI
– – – – ↗ ↗
Development of new
radiopharmaceuticals for PET
use in general
– – – – ↗ ↗
Standardise imaging protocols – – – – ↔ ↔
Standardise image interpretation
criteria
– – – – ↔ ↔
Definition of key clinical
applications
– – – – ↗ ↔
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with PET and MRI should provide tools with which to
monitor the differential response expected from the different
phenotypes of cancer cells present.
The final presentation looked at a promising technique for
MRI, known as chemical exchange saturation transfer
(CEST) [73, 74] with glucoCEST, which uses the hydroxyl
groups of the glucose molecule to study glucose uptake and
metabolism [75]. The glucoCEST imaging procedure uses
millimolar amounts of contrast and demonstrates vascular
and extracellular signals and may potentially be able to
follow metabolic products of the agent through various
phases of the Krebs cycle. This could provide an interesting
comparison with [18F]FDG, which is trapped upon entry into
the cell and does not proceed through the metabolic cascade.
A further agent which has already been tested in tumour
patients is 3-O-methyl-D-glucose (OMG) [76–78]. Of note,
chemical shift selective CEST, e.g. amide proton transfer,
works best with very high magnetic field strengths and, thus,
is not applicable with current whole-body PET/MRI sys-
tems. However, the glucose injection approach employing
the difference of images before and after injection again
provides glucose-related selectivity at clinical field strengths
and lower chemical shift selectivity.
This dialogue board brought out some of the liveliest
discussions, attesting to the keen interests of the audience in
reviewing new, less standard-of-care applications of PET/
MRI. A strong desire towards implementing existing MR-
only techniques (e.g. CEST imaging, hyperpolarisation) into
PET/MRI was expressed. Whilst progress in conceptualisa-
tion of such ideas was evident, practical implementations
were lagging behind, pr imar i ly because these
implementations are linked to higher investments in person-
nel and infrastructure, and as such may be limited to a few
selected sites. In that case, it becomes ever more important
to share new insights into emerging areas in order to ensure
expedited translation into the clinic where and whenever
applicable.
Round Table Discussions
Round Table 1: Reading PET/MRI—Who and
How?
Round Table 1 hosted a spirited debate about the best way to
report clinical PET/MRI scans. The panellists represented
the radiological, nuclear medicine and hybrid imaging
communities. From the opening remarks of each, it was
clear that this issue is one that had been prominent in the
panellists’ minds for some time.
The majority of the panellists introduced PET/MRI in
their institutions with clinical scanning reported by dual
readers—an MRI expert and a nuclear medicine expert. This
was seen as a sensible approach in the initial start-up phase,
but some felt that this would be financially unsustainable in
the long term. All agreed that it was imperative that the
potential of MRI should be fully exploited and not Bdumbed
down^ as some panellists suggested happened to the CT
component of PET/CT whenever its use is limited to Blow
dose^ mode for anatomical localisation and attenuation
correction only.
Having accepted that dual reporting was not the future for
PET/MRI in the long term, the debate moved to whether a
dual certified radiology/nuclear medicine-trained individual
is appropriate or, in fact, whether a new specialisation as a
Bhybrid imager^ would be more appropriate. The hybrid
imager would be someone particularly trained in the
interpretation of multi-parametric image data in an inte-
grated, synergistic fashion, rather than as a pair of
complementary scans acquired in a single session. Training
programmes will need to be modified to reflect any such
changes in specialisation which, unfortunately, still happen
at a national level even within the European Union. The
respective professional organisations will need to cooperate
to produce the best outcome and not revert to trying to
simply Bprotect their patch^.
Eventually, the healthcare environment will need to
accept the statement made by one of the panellists: BHigh-
end technology imaging requires high-end reading^; local
variations may apply.
Round Table 2: Imaging Versus Liquid Biopsy
The participants in this round table discussion emphasised
that liquid biopsy today is able to characterise multiple
mutations that may not be present in every individual lesion
and, therefore, is not prone to the sampling errors associated
with conventional tissue biopsy using fine needle aspiration
or core biopsy samples. From this point of view, it was
suggested that it was an extremely valuable technology for
monitoring the development of resistance in cancers. Liquid
biopsy may point to the use of different imaging biomarkers
Table 8. Progress indicators for PET/MRI for applications in emerging areas
2012 2013 2014 2015 2016 2017
Fully integrated PET/MRI exclusively offers the largest variety of multi-parametric biomarkers ↔ ↗ ↑ ↑ ↑ ↑
Validation of advanced multi-parametric biomarkers in clinical research (beyond Bimage fusion^) ↘ ↔ ↗ ↗ ↔ ↔
Contributions of small animal imaging to the understanding of multi-parametric biomarkers ↔ ↗ ↑ ↑ ↗ ↗
Using standardised approaches for assessing the accuracy of PET/MRI and towards multi-parametric
image analysis
– – – ↗ ↔ ↔
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if multiple driver mutations are demonstrated in the sample.
Panellists pointed to the massive imbalance between the
relatively modest amount spent on diagnostic techniques
compared with the high cost of the therapies that are often
delivered without adequately characterising the most appro-
priate pathway to target prior to treatment. One panellist
called for Bspending more money on tests that help us
understand disease and tailor much more expensive
therapies.^
It was clear from the discussion that liquid biopsy and
imaging are complementary rather than competing technol-
ogies. Liquid biopsy is able to identify different phenotypes
in cancer cells but remains a global measure, whereas
imaging with PET/MRI using appropriate imaging probes
can be used to identify differences between lesions due to
clonal variation which may have an influence on the choice
of the most appropriate therapy, especially when using a
regionally targeted approach such as with radiotherapy or
organ-specific chemotherapy or radioembolisation.
The discussion diverted multiple times onto a topic that
surfaced repeatedly during this workshop, which is the
wealth of data that we have at hand, augmented by imaging-
based biomarker information, and that generally goes
untouched. The panel argued that Beven if we do not
interpret all information [aka data] today, we may need these
data for later^, pointing to the ever-evolving field of big data
and deep learning. Such a data repository would clearly
benefit from wrapping any type of non-imaging (and
imaging) data in a structured, DICOM-type manner so as
make them accessible on existing viewing and storage
systems, such as PACS.
Conclusion
In continuation of the discussions of the 5th Tübingen
workshop, this meeting has focussed much more on
emerging areas and provided a balance between state-of-
the-art practices and strategies (BWhere to go?^) in key areas
of application (oncology and neurology). The dialogue
boards were complemented with highlight presentations of
promising applications of PET/MRI, such as RTP and the
assessment of the tumour microenvironment, an area that
clearly would benefit from cross-speciality engagement
much beyond that required for operating a PET/MRI
programme.
Two interesting take-home messages from this year’s
meeting pertinent to the clinical community were as follows:
(a) PET/MRI is perhaps better used as a local tumour
phenotyping methodology rather than as a competitor to
whole-body PET/CT imaging (except for paediatrics), and
(b) the simultaneity of PET and MRI as offered by fully
integrated PET/MRI systems is seen as useful mainly for
increased patient comfort—for the actual use of PET and
MRI information, maximisation of stand-alone performance
and quality was understood as key.
In the summary review talk, the theme given to this
year’s workshop was Bglobal warming^. We have come a
long way from the 1st workshop in 2012 when the topic was
mainly Bhow does PET/MRI compare with PET/CT^. Over
the years and through the engagement of many avid users
and pioneers, the potential and capabilities of PET/MRI have
been shaped and are becoming much more apparent.
Together, the PET/MRI community has created a space for
engagement of many capable individuals and groups. A
global team effort is of the essence in turning this potential
into a reality with real value for the research community and
for patients. Global warming was chosen, because like
climate change, PET/MRI is now known to many people. It
has gone global and it has started to warm people up to its
use.
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